

NCT ID	NCT03638206
Title	Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Phase	Phase 1/Phase 2
Date Added	2018-08-20
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	CAR-T cell immunotherapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03772561
Title	Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
Phase	Phase 1
Date Added	2018-12-11
Location	Singapore
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	AZD5363+Olaparib+Durvalumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT02343991
Title	Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound
Phase	Not Applicable
Date Added	2015-01-22
Location	Canada
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Transcranial ExABlate
Tags	MSS/ MMRp
NCT ID	NCT04991948
Title	Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2021-08-05
Location	Florida, United States Belgium
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	CYAD-101, FOLFOX, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05299840
Title	Impact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer
Phase	Not Applicable
Date Added	2022-03-29
Location	France

Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03865082
Title	Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Phase	Phase 2
Date Added	2019-03-06
Location	Arizona, United States California, United States Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab, Tilsotolimod, Opdivo, Yervoy
Tags	MSS/ MMRp
NCT ID	NCT03366155
Title	Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Phase	Phase 2
Date Added	2017-12-08
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	5FU, cetuximab, FUDR-Dex, Irinotecan, Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter, OneRNA, oxaliplatin, panitumumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03297606
Title	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase	Phase 2
Date Added	2017-09-29
Location	Canada
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	Axitinib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Nivolumab plus Ipilimumab, Olaparib, palbociclib, Sunitinib, Temozolimus, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03488953
Title	Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases
Phase	Not Applicable
Date Added	2018-04-05
Location	Germany
Prior IO Allowed	No

CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT04660812
Title	An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Phase	Phase 1, Phase 2
Date Added	2020-12-09
Location	Alabama, United States Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States France Italy Korea, Republic of Spain United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab
Tags	MSS/ MMRp